Meet Ravi Vij: Indian-origin cancer specialist honoured with a prestigious US professorship for redefining blood cancer treatment
Image: WashU Ravi Vij's journey from New Delhi to the forefront of blood cancer treatment Leading research that changed treatment approaches More than 200 scientific
Image: WashU Ravi Vij's journey from New Delhi to the forefront of blood cancer treatment Leading research that changed treatment approaches More than 200 scientific publications A leader in stem cell transplantation Mentor, teacher and academic leader Recognised across the oncology community What the distinguished professorship means A career dedicated to improving patient outcomes The path from a medical college in New Delhi to one of the most prestigious academic appointments in American medicine is rarely straightforward. Ravi Vij followed that journey while building a career dedicated to understanding and treating blood cancers. The Indian-origin physician-scientist was recently named the inaugural Jeffrey S. and Prue H. Gershman Distinguished Professor at Washington University School of Medicine in St. Louis, a recognition of his contributions to cancer research, patient care and medical education. The appointment highlights a career that has helped advance treatment options for multiple myeloma and other blood cancers while establishing Vij as one of the leading figures in his field.Ravi Vij's medical journey began at Maulana Azad Medical College in New Delhi, one of India's most respected medical institutions. After completing his medical education, he moved to the United States for advanced training in oncology, haematology and bone marrow transplantation at Washington University School of Medicine.He joined the university's faculty in 2000 and steadily built a reputation as both a clinician and researcher.Over the years, he became a key figure in WashU Medicine's cancer programme, helping strengthen its standing in blood cancer research and treatment.Much of Vij's career has centred on multiple myeloma, a cancer that develops in plasma cells found within bone marrow.
The disease remains one of the most common forms of blood cancer and has long presented significant challenges for doctors and researchers.During the past two decades, treatment options for multiple myeloma have improved dramatically. Advances in immunotherapy, targeted drugs and stem cell transplantation have extended survival rates and improved quality of life for many patients. Vij has been among the physician-scientists contributing to that progress through both clinical care and research.His work has focused on understanding the biological mechanisms of blood cancers and identifying better ways to treat them.Vij has spent years leading clinical trials that explored new therapies for blood cancers. Several of these studies examined innovative immunotherapy approaches and stem cell transplant strategies that later became part of standard treatment practices.At Siteman Cancer Center, where he treats patients and conducts research, Vij has focused on improving the understanding of multiple myeloma and related blood disorders. His research has helped advance knowledge of how these diseases develop and respond to treatment.The findings from such studies contribute to the growing field of precision medicine, which seeks to tailor therapies to the unique characteristics of individual patients.Throughout his career, Vij has authored more than 200 peer-reviewed scientific papers focused on multiple myeloma, stem cell transplantation, immunotherapy and related blood disorders.His publications have contributed to a broader understanding of blood cancers and informed treatment decisions in cancer centres around the world. This body of work has helped establish him as a respected voice within the international oncology community.Stem cell transplantation remains one of the most important treatment options for several blood cancers.
The BriefWire